Friday, June 12, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 145 of 1,261
  1. US 11866502

    Anti-FGFR2 antibodies and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. Β· Granted Jan 9, 2024 Β· Expires Jan 4, 2044

    granted
  2. US 11865186

    Gene therapy treatment of atrial fibrillation

    Northwestern University Β· Granted Jan 9, 2024 Β· Expires Jan 4, 2044

    granted
  3. US 11865098

    Methods and compositions for treating excessive sleepiness

    AXSOME MALTA LTD. Β· Granted Jan 9, 2024 Β· Expires Jan 4, 2044

    granted
  4. US 11865145

    Compositions and methods for maintaining and restoring a healthy gut barrier

    Finch Therapeutics Holdings LLC Β· Granted Jan 9, 2024 Β· Expires Jan 4, 2044

    granted
  5. US 11865126

    Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin

    Compass Pathfinder Limited Β· Granted Jan 9, 2024 Β· Expires Jan 4, 2044

    granted
  6. US 11866710

    Transmembrane protease, serine 6 (TMPRSS6) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. Β· Granted Jan 9, 2024 Β· Expires Jan 4, 2044

    granted
  7. US 11866503

    Methods for treating inflammatory conditions of the airway or lungs by administering antagonist monoclonal antibodies to interleukin-33 and interleukin-4 receptor

    REGENERON PHARMACEUTICALS, INC. Β· Granted Jan 9, 2024 Β· Expires Jan 4, 2044

    granted
  8. US 11865111

    Antiviral drugs targeting the N-terminal domain (NTD) of the coronavirus spike receptor binding domain (RBD)

    The Government of the United States, as represented by the Secretary of the Army Β· Granted Jan 9, 2024 Β· Expires Jan 4, 2044

    granted
  9. US 11866446

    Inhibitors of APOL1 and methods of using same

    Vertex Pharmaceuticals Incorporated Β· Granted Jan 9, 2024 Β· Expires Jan 4, 2044

    granted
  10. US 11866701

    Complement component C3 iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. Β· Granted Jan 9, 2024 Β· Expires Jan 4, 2044

    granted
  11. US 11866439

    Ion channel modulators

    PRAXIS PRECISION MEDICINES, INC. Β· Granted Jan 9, 2024 Β· Expires Jan 4, 2044

    granted
  12. US 11865155

    Plant extract obtained from Morus plant leaves which has an IC50 value to inhibit a-glucosidase I at a concentration of less than 90 uG/ml, compositions containing same, method of extraction and uses thereof

    Botanic Century (Beijing) Co. Ltd. Β· Granted Jan 9, 2024 Β· Expires Jan 4, 2044

    granted
  13. US 11866491

    Antibody for binding to interleukin 4 receptor

    SuZhou Connect Biopharmaceuticals, Inc. Β· Granted Jan 9, 2024 Β· Expires Jan 4, 2044

    granted
  14. US 11865157

    Compositions and methods of targeting cancer stem cells

    The Board of Regents of the University of Texas System Β· Granted Jan 9, 2024 Β· Expires Jan 4, 2044

    granted
  15. US 11865140

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Iovance Biotherapeutics, Inc. Β· Granted Jan 9, 2024 Β· Expires Jan 4, 2044

    granted
  16. US 11866418

    Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors

    BioCryst Pharmaceuticals, Inc. Β· Granted Jan 9, 2024 Β· Expires Jan 4, 2044

    granted
  17. US 11865174

    Universal vaccine platform

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY Β· Granted Jan 9, 2024 Β· Expires Jan 4, 2044

    granted
  18. US 11866794

    Cas-ready mouse embryonic stem cells and mice and uses thereof

    REGENERON PHARMACEUTICALS, INC. Β· Granted Jan 9, 2024 Β· Expires Jan 4, 2044

    granted
  19. CA 3259886

    DISPOSITIFS DE DÉPLACEMENT D'IGE-FCERI

    UNIV AARHUS [DK] Β· Granted Jan 4, 2024 Β· Expires Dec 30, 2043

    granted
  20. CA 3260379

    VACCIN CONTRE LE VIRUS D'EPSTEIN-BARR

    BAVARIAN NORDIC AS [DK] Β· Granted Jan 4, 2024 Β· Expires Dec 30, 2043

    granted
  21. CA 3260357

    RÉGIME DE PRIMO-IMMUNISATION DE VIRUS DE LA VACCINE ANKARA (MVA) ET DE PETIT ARN ACTIVATEUR (VRP) MODIFIÉS RECOMBINANTS

    BAVARIAN NORDIC AS [DK] Β· Granted Jan 4, 2024 Β· Expires Dec 30, 2043

    granted
  22. CA 3258751

    LIGNΓ‰E CELLULAIRE DE MAMMIFÈRE POUR LA PRODUCTION DE VIRUS DE LA VACCINE ANKARA MODIFIΓ‰ (MVA)

    BAVARIAN NORDIC AS [DK] Β· Granted Jan 4, 2024 Β· Expires Dec 30, 2043

    granted
  23. IT 202200013882

    PRODOTTO DI FERMENTAZIONE PER IL TRATTAMENTO DI MALATTIE INFIAMMATORIE.

    ALFASIGMA SPA [IT] Β· Granted Jan 4, 2024 Β· Expires Dec 30, 2043

    granted
  24. US 11857528

    Methods of providing solriamfetol therapy to subjects with impaired renal function

    AXSOME MALTA LTD. Β· Granted Jan 2, 2024 Β· Expires Dec 28, 2043

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.